Biden chooses semaglutide for next round of Medicare price negotiations—Trump gets final say
The final list also included diabetes drugs sold by Boehringer Ingelheim and Merck. The first round of drug price negotiations reduced the Medicare prices for 10 popular drugs by up to 79%.